Cargando…

Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2

BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Bras, Jose, Guerreiro, Rita, Ribeiro, Maria, Morgadinho, Ana, Januario, Cristina, Dias, Margarida, Calado, Ana, Semedo, Cristina, Oliveira, Catarina, Hardy, John, Singleton, Andrew
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248204/
https://www.ncbi.nlm.nih.gov/pubmed/18211709
http://dx.doi.org/10.1186/1471-2377-8-1
_version_ 1782150979704061952
author Bras, Jose
Guerreiro, Rita
Ribeiro, Maria
Morgadinho, Ana
Januario, Cristina
Dias, Margarida
Calado, Ana
Semedo, Cristina
Oliveira, Catarina
Hardy, John
Singleton, Andrew
author_facet Bras, Jose
Guerreiro, Rita
Ribeiro, Maria
Morgadinho, Ana
Januario, Cristina
Dias, Margarida
Calado, Ana
Semedo, Cristina
Oliveira, Catarina
Hardy, John
Singleton, Andrew
author_sort Bras, Jose
collection PubMed
description BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients. This series comprises 66 patients selected from a consecutive series of 132 patients. This selection was made in order to include only early onset patients (age at onset below 50 years) or late-onset patients with a positive family history (at least one affected relative). All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis. RESULTS: We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or compound heterozygosity for PRKN, and heterozygosity for LRRK2. CONCLUSION: Mutations are common in Portuguese patients with Parkinson's disease, and these results clearly have implications not only for the genetic diagnosis, but also for the genetic counseling of these patients.
format Text
id pubmed-2248204
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22482042008-02-20 Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 Bras, Jose Guerreiro, Rita Ribeiro, Maria Morgadinho, Ana Januario, Cristina Dias, Margarida Calado, Ana Semedo, Cristina Oliveira, Catarina Hardy, John Singleton, Andrew BMC Neurol Research Article BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients. This series comprises 66 patients selected from a consecutive series of 132 patients. This selection was made in order to include only early onset patients (age at onset below 50 years) or late-onset patients with a positive family history (at least one affected relative). All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis. RESULTS: We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or compound heterozygosity for PRKN, and heterozygosity for LRRK2. CONCLUSION: Mutations are common in Portuguese patients with Parkinson's disease, and these results clearly have implications not only for the genetic diagnosis, but also for the genetic counseling of these patients. BioMed Central 2008-01-22 /pmc/articles/PMC2248204/ /pubmed/18211709 http://dx.doi.org/10.1186/1471-2377-8-1 Text en Copyright © 2008 Bras et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bras, Jose
Guerreiro, Rita
Ribeiro, Maria
Morgadinho, Ana
Januario, Cristina
Dias, Margarida
Calado, Ana
Semedo, Cristina
Oliveira, Catarina
Hardy, John
Singleton, Andrew
Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title_full Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title_fullStr Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title_full_unstemmed Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title_short Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
title_sort analysis of parkinson disease patients from portugal for mutations in snca, prkn, pink1 and lrrk2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248204/
https://www.ncbi.nlm.nih.gov/pubmed/18211709
http://dx.doi.org/10.1186/1471-2377-8-1
work_keys_str_mv AT brasjose analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT guerreirorita analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT ribeiromaria analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT morgadinhoana analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT januariocristina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT diasmargarida analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT caladoana analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT semedocristina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT oliveiracatarina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT hardyjohn analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2
AT singletonandrew analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2